UCDCC#269: A Pilot Study of Interlesional IL-2 and RT in Patients With NSCLC.
Status:
Completed
Trial end date:
2020-01-10
Target enrollment:
Participant gender:
Summary
The advent of checkpoint blockade immunotherapy has revolutionized the management of
metastatic non-small cell lung cancer (NSCLC). Despite the promising evidence for deep and
durable responses with these agents the majority of patients fail to respond. The
investigators hypothesize that a novel strategy combining radiotherapy and intralesional
interleukin-2 (IL-2), a signaling molecule and member of the cytokine family involved in the
activation of leukocytes and lymphocytes, may overcome resistance to checkpoint blockade
therapy and offer significant clinical benefit to patients who fail to respond to checkpoint
blockade alone. The investigators propose a microtrial testing the feasibility of a bold
combinatorial immunotherapy strategy consisting of radiotherapy (RT), intralesional IL-2, and
check-point blockade for metastatic non-small cell lung cancer patients who have progressed
after checkpoint inhibition. IL-2 can upregulate PD-1 expression and activate T-cells.